Medical treatment and its advances of pancreatic neuroendocrine neoplasms
10.19538/j.cjps.issn1005-2208.2019.09.12
- Author:
Luo-hai CHEN
1
;
Jie CHEN
1
Author Information
1. Department of Gastroenterology,the First Affiliated Hospital,Sun Yat-sen University Guangzhou 510080,China
- Publication Type:Journal Article
- Keywords:
pancreatic neuroendocrine neoplasms;
medical treatment;
biotherapy;
targeted therapy;
chemotherapy
- From:
Chinese Journal of Practical Surgery
2019;39(09):929-934
- CountryChina
- Language:Chinese
-
Abstract:
The incidence rate of pancreatic neuroendocrine neoplasms(pNENs)is continuously increasing.Since 20% to64% of pNENs develops metastatic disease when diagnosed and functional pNENs is quite common,medical treatment is of great importance for pNENs.Somatostatin analogues(SSAs)is one of the major medical treatments for pNENs and the new generation of SSAs cannot replace the role of lanreotide autogel and octreotide long-acting repeatable(LAR)for pancreatic neuroendocrine tumor(pNET)with low proliferative index and positive expression of somatostatin receptors(SSTRs).Everolimus and sunitinib are two targeted treatments recommended for pNET.Clinical trials of other targeted treatments are gradually conducted with some of them already reached phase Ⅲ.Chemotherapy is usually applied in pNENs with high growth rate or poorly-differentiated neuroendocrine carcinoma(NEC).Most clinical trials of new chemotherapy scheme are designed for NEC.Peptide receptor radionuclide therapy(PRRT) may have important value in pNET positively expressing SSTRs.Preliminary data of immunotherapy for pNENs did not show very promising result and studies of different medical treatments combinations for pNENs are still under exploration.In general,although medical treatments for pNENs had achieved great advances,there is still a long way to go before many new treatments can be used in pNENs.
